AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$CTRVP

Fisher Danina purchased $10K of CTRVP

Fisher Danina purchased 200,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 on 2026-09-29.

Original reporting
SEC EDGAR · Fisher Danina
Published Oct 2, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CTRVP
Neutral
low confidence
Mentioned
$CTRVP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTRVPNeutralLow
01

Why it matters

The insider transaction is disclosed via a Form 4, providing primary source information but the monetary size is trivial.

02

Market read

Small insider buy with limited market impact; unlikely to affect trading decisions.

03

What to watch

The low price per share suggests the stock is still highly speculative; the director's stake remains modest.

Relevance 4/10Novelty 2/10Timing: filing date 2026‑10‑02

Background

Hepion Pharmaceuticals (CTRVP) is a biotech company listed on the US OTC market. The filing reports a director's recent share purchase.

Company-level read

Ticker impact

$CTRVPNeutralLow confidence
Context

Director Fisher Danina bought 200,000 shares of Hepion Pharmaceuticals at $0.05 each, totaling $10,000, disclosed via a Form 4 filing.

Expected impact

likely slight upward pressure as the market prices in the insider buy

Evidence & confidence

The transaction is a small open‑market purchase by a director; the amount is negligible relative to float and typical trading volume.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The purchase may be a routine portfolio adjustment rather than a strong endorsement.

Key entities

  • Director
    Fisher Danina

    Director of Hepion Pharmaceuticals who purchased shares.

  • Company
    Hepion Pharmaceuticals, Inc.

    Biotech firm whose ticker is CTRVP.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CTRVP insider trading history →

Related articles

OCT 9
$CTRVPMed

Hepion Pharmaceuticals, Inc. (CTRVP): Completion of Acquisition or Disposition of Assets

Hepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement. On October 6, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”),

SEC EDGAR 8-K2 min